特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
948131

急性呼吸窮迫症候群(ARDS):疫学予測 (~2030年)

Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
急性呼吸窮迫症候群(ARDS):疫学予測 (~2030年)
出版日: 2020年07月01日
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

急性呼吸窮迫症候群(ARDS)は、重症患者で急速に進行する疾患です。ARDSの原因は、肺への直接的または間接的な損傷の2つのカテゴリに分類されます。肺への直接的な損傷には、肺炎、誤嚥、外傷などが含まれますが、肺への間接的な損傷には、膵臓の炎症、重度の感染症(敗血症とも呼ばれます)、輸血、火傷、投薬反応などがあります。 ARDSのいくつかの症状は、息切れ、咳、発熱です。場合によっては、ARDS患者は心拍数が速く、呼吸が速いこともあります。 ARDSのリスクを増大させる可能性のあるいくつかのリスク要因には、肥満、アルコール乱用、化学療法、血中の低タンパク質が含まれます。

当レポートでは、世界の主要7市場 (米国・ドイツ・英国・イタリア・フランス・スペイン・日本) における急性呼吸窮迫症候群(ARDS)市場について調査し、市場概要、疾患の背景・疫学、各国市場などについて分析しています。

第1章 主な洞察

第2章 エグゼクティブサマリー

第3章 SWOT分析

第4章 急性呼吸窮迫症候群(ARDS):疫学の概要

  • 2017年の疫学シェア(%)ARDSの分布
  • 2030年の疫学シェア(%)ARDSの分布

第5章 急性呼吸窮迫症候群(ARDS):疾患の背景と概要

  • イントロダクション
    • 急性肺損傷および急性呼吸窮迫症候群(ARDS)のコンセンサス定義
    • ARDSのベルリン定義の発展
    • AECCの定義およびそれに続く急性呼吸窮迫症候群(ARDS)のベルリン定義に関する問題
  • 原因とリスク要因
    • 急性呼吸窮迫症候群(ARDS)の危険因子
  • 急性呼吸窮迫症候群(ARDS)の病態生理
    • ARDSの炎症プロセス
    • けがの最初のイベント
    • 内皮損傷
    • ARDSにおける炎症と肺障害の特定のメディエーター
    • ARDSにおける呼吸生理学の変更
    • 遺伝学
  • 急性呼吸窮迫症候群(ARDS)の病期
  • 人工呼吸器誘発性肺損傷(VILI)
  • VILIの主要な決定要因
    • VILIの人工呼吸器の決定要因
    • VILIの患者決定要因
  • 急性呼吸窮迫症候群(ARDS)の診断
    • ARDSの画像技術
    • ARDSの画像所見
    • 鑑別疾患

第6章 認可施設

第7章 疫学と患者人口

  • 主な調査結果
  • 調査手法

第8章 主要7ヶ国市場の疫学分析

  • 主要7ヶ国市場における急性呼吸窮迫症候群(ARDS)の総患者人口
  • 主要7ヶ国市場における急性呼吸窮迫症候群(ARDS)の総患者人口:重症度別

第9章 米国の疫学

  • 仮定と根拠
  • 総患者人口
  • 総患者人口:重症度別
  • 総患者人口:リスク因子別

第10章 欧州5ヶ国疫学

  • ドイツの疫学
    • 仮定と根拠
    • 総患者人口
    • 総患者人口:重症度別
    • 総患者人口:リスク因子別
  • フランスの疫学
  • イタリアの疫学
  • スペインの疫学
  • 英国の疫学

第11章 日本の疫学

  • 仮定と根拠
  • 総患者人口
  • 総患者人口:重症度別
  • 総患者人口:リスク因子別
図表

List of Tables

  • Table 1: Definition of Acute Respiratory Distress Syndrome (ARDS)
  • Table 2: American European Consensus Conference Criteria for Acute Lung Injury (ALI) and the Acute Respiratory Distress Syndrome (ARDS)
  • Table 3: Berlin Definition of Mild, Moderate, and Severe Acute Respiratory Distress Syndrome (ARDS)
  • Table 4: Factors That Distinguish ARDS, CHF, and Pneumonia
  • Table 5: Total Incident Population of ARDS in the 7MM (2017-2030)
  • Table 6: Severity-specific Incident Population of ARDS in the 7MM (2017-2030)
  • Table 7: Total Incident Population of ARDS in the US (2017-2030)
  • Table 8: Severity-specific Incident Population of ARDS in the US (2017-2030)
  • Table 9: Incidence of ARDS by Risk Factors in the US (2017-2030)
  • Table 10: Total Incident Population of ARDS in Germany (2017-2030)
  • Table 11: Severity-specific Incident Population of ARDS in Germany (2017-2030)
  • Table 12: Incidence of ARDS by Risk Factors in Germany (2017-2030)
  • Table 13: Total Incident Population of ARDS in France (2017-2030)
  • Table 14: Severity-specific Incident Population of ARDS in France (2017-2030)
  • Table 15: Incidence of ARDS by Risk Factors in France (2017-2030)
  • Table 16: Total Incident Population of ARDS in Italy (2017-2030)
  • Table 17: Severity-specific Incident Population of ARDS in Italy (2017-2030)
  • Table 18: Incidence of ARDS by Risk Factors in Italy (2017-2030)
  • Table 19: Total Incident Population of ARDS in Spain (2017-2030)
  • Table 20: Severity-specific Incident Population of ARDS in Spain (2017-2030)
  • Table 21: Incidence of ARDS by Risk Factors in Spain (2017-2030)
  • Table 22: Total Incident Population of ARDS in the UK (2017-2030)
  • Table 23: Severity-specific Incident Population of ARDS in the UK (2017-2030)
  • Table 24: Incidence of ARDS by Risk Factors in the UK (2017-2030)
  • Table 25: Total Incident Population of ARDS in Japan (2017-2030)
  • Table 26: Severity-specific Incident Population of ARDS in Japan(2017-2030)
  • Table 27: Incidence of ARDS by Risk Factors in Japan (2017-2030)

List of Figures

  • Figure 1: Acute Respiratory Distress Syndrome (ARDS) SWOT Analysis
  • Figure 2: Common Symptoms of Acute Respiratory Distress Syndrome (ARDS)
  • Figure 3: Risk Factors of Acute Respiratory Distress Syndrome (ARDS)
  • Figure 4: Pathophysiology of ABPA
  • Figure 5: Proposed Algorithm for the Diagnosis of CPA
  • Figure 6: Algorithm for the Diagnosis of ABPA in Asthma
  • Figure 7: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in the 7MM Countries (2017-2030)
  • Figure 8: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in the 7MM Countries (2017-2030)
  • Figure 9: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in the United States (2017-2030)
  • Figure 10: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in the United States (2017-2030)
  • Figure 11: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in Germany (2017-2030)
  • Figure 12: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in Germany (2017-2030)
  • Figure 13: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in France (2017-2030)
  • Figure 14: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in France (2017-2030)
  • Figure 15: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in Italy (2017-2030)
  • Figure 16: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in Italy (2017-2030)
  • Figure 17: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in Spain (2017-2030)
  • Figure 18: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in Spain (2017-2030)
  • Figure 19: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in the UK (2017-2030)
  • Figure 20: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by type in the UK (2017-2030)
  • Figure 21: Acute Respiratory Distress Syndrome (ARDS) Prevalent Cases in Japan (2017-2030)
  • Figure 22: Acute Respiratory Distress Syndrome (ARDS) Diagnosed and treated pool by types in Japan (2017-2030)
目次
Product Code: DIEI0002

DelveInsight's 'Acute Respiratory Distress Syndrome (ARDS)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Acute Respiratory Distress Syndrome (ARDS) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Acute Respiratory Distress Syndrome (ARDS) Understanding

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs, making breathing difficult or impossible. Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs with the acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality.

The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions. The few symptoms of ARDS are shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risks factors that may escalate the risk for ARDS; this involves obesity, alcohol abuse, chemotherapy, low-protein in blood.

Acute Respiratory Distress Syndrome (ARDS) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of ARDS, Severity-specific Incidence of ARDS and Incidence of ARDS by Risk Factors scenario of Acute Respiratory Distress Syndrome (ARDS) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Acute Respiratory Distress Syndrome (ARDS) Detailed Epidemiology Segmentation

  • In the 7MM, the total incident population of ARDS is estimated to be 799,872 in 2017.
  • Generally, the highest number of incident cases were assessed for ARDS due to pneumonia, in all the 7MM countries, except the United Kingdom, in which sepsis was the primary risk factor for ARDS.
  • The estimates show a higher incidence of ARDS in the United States with 495,655 cases in 2017.

Scope of the Report:

  • The report covers the descriptive overview of Acute Respiratory Distress Syndrome (ARDS), explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Acute Respiratory Distress Syndrome (ARDS).
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Acute Respiratory Distress Syndrome (ARDS), Total Diagnosed and Treated Cases of Acute Respiratory Distress Syndrome (ARDS).

Report Highlights:

  • Eleven-Year Forecast of Acute Respiratory Distress Syndrome (ARDS)
  • 7MM Coverage
  • Total Incident Population of ARDS
  • Severity-specific Incidence of ARDS
  • Incidence of ARDS by Risk Factors
  • Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is estimated to increase at a CAGR of 1.07%
  • Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM is projected to rise at a CAGR of 0.92%.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Acute Respiratory Distress Syndrome (ARDS)?
  • What is the historical Acute Respiratory Distress Syndrome (ARDS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Acute Respiratory Distress Syndrome (ARDS) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acute Respiratory Distress Syndrome (ARDS)?
  • Out of the countries mentioned above, which country would have the highest prevalent population of Acute Respiratory Distress Syndrome (ARDS) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)? 

Reasons to buy:

The Acute Respiratory Distress Syndrome (ARDS) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Acute Respiratory Distress Syndrome (ARDS) market.
  • Quantify patient populations in the 7MM Acute Respiratory Distress Syndrome (ARDS) market to improve product design, pricing, and launch plans.
  • The Acute Respiratory Distress Syndrome (ARDS) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Acute Respiratory Distress Syndrome (ARDS) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Acute Respiratory Distress Syndrome (ARDS): Epidemiology Overview at a Glance

  • 4.1 Total Epidemiology Share (%) Distribution of ARDS in 2017
  • 4.2 Total Epidemiology Share (%) Distribution of ARDS in 2030

5 Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview

  • 5.1 Introduction
    • 5.1.1 Consensus Definitions of Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
    • 5.1.2 Development of Berlin Definition of ARDS
    • 5.1.3 Problems with the AECC definition and subsequent Berlin definition of acute respiratory distress syndrome (ARDS)
  • 5.2 Causes and Risk Factors
    • 5.2.1 Risk Factors of Acute Respiratory Distress Syndrome (ARDS)
  • 5.3 Pathophysiology of Acute Respiratory Distress Syndrome (ARDS)
    • 5.3.1 Inflammatory Processes in ARDS
    • 5.3.2 The initial event of injury
    • 5.3.3 Endothelial Damage
    • 5.3.4 Specific Mediators of Inflammation and Lung Damage in ARDS
    • 5.3.5 Altered Pulmonary Physiology in ARDS
    • 5.3.6 Genetics
  • 5.4 Stages of Acute Respiratory Distress Syndrome (ARDS)
  • 5.5 Ventilator-Induced Lung Injury (VILI)
  • 5.6 Major Determinants of VILI
    • 5.6.1 Ventilator determinants of VILI
    • 5.6.2 Patient determinants of VILI
  • 5.7 Diagnosis of Acute Respiratory Distress Syndrome (ARDS)
    • 5.7.1 Imaging techniques in ARDS
    • 5.7.2 Imaging findings in ARDS
    • 5.7.3 Differential Diagnosis

6 Recognized Establishments

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Methodology

8 7MM Epidemiology Analysis

  • 8.1 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM
  • 8.2 Severity-specific Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the 7MM

9 United States Epidemiology

  • 9.1 Assumptions and Rationale
  • 9.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United States
  • 9.3 Severity-specific Incident Population of ARDS in the United States
  • 9.4 Incident Population of ARDS by Risk Factors in the United States

10 EU5 Epidemiology

  • 10.1 Germany Epidemiology
    • 10.1.1 Assumptions and Rationale
    • 10.1.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Germany
    • 10.1.3 Severity-specific Incidence of ARDS in Germany
    • 10.1.4 Incident Population of ARDS by Risk Factors in Germany
  • 10.2 France Epidemiology
    • 10.2.1 Assumptions and Rationale
    • 10.2.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), in France
    • 10.2.3 Severity-specific Incidence of ARDS in France
    • 10.2.4 Incident Population of ARDS by Risk Factors in France
  • 10.3 Italy Epidemiology
    • 10.3.1 Assumptions and Rationale
    • 10.3.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Italy
    • 10.3.3 Severity-specific Incidence of ARDS in Italy
    • 10.3.4 Incident Population of ARDS by Risk Factors in Italy
  • 10.4 Spain Epidemiology
    • 10.4.1 Assumptions and Rationale
    • 10.4.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Spain
    • 10.4.3 Severity-specific Incidence of ARDS in Spain
    • 10.4.4 Incident Population of ARDS by Risk Factors in Spain
  • 10.5 United Kingdom Epidemiology
    • 10.5.1 Assumptions and Rationale
    • 10.5.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in the United Kingdom
    • 10.5.3 Severity-specific Incidence of ARDS in the United Kingdom
    • 10.5.4 Incident Population of ARDS by Risk Factors in the United Kingdom

11 Japan Epidemiology

  • 11.1 Assumptions and Rationale
  • 11.2 Total Incident Population of Acute Respiratory Distress Syndrome (ARDS), ARDS in Japan
  • 11.3 Severity-specific Incidence of ARDS in Japan
  • 11.4 Incident Population of ARDS by Risk Factors in Japan
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.